
SNYR Stock Forecast & Price Target
SNYR Analyst Ratings
Bulls say
Synergy CHC is positioned for continued growth and success with its strong performance in expanding the FOCUSfactor brand and capitalizing on the growing brain health supplements and energy RTD markets. Despite some challenges and competitive industry, the company has shown resilience and profitability, and is expected to make significant progress and growth in the next several years. With a solid balance sheet and potential catalysts on the horizon, such as new products and international expansion, the stock is undervalued and presents a promising investment opportunity.
Bears say
Synergy CHC is facing financial difficulties, as shown by their weak Q1 results with a significant decrease in revenue and negative Pro EPS. Despite a lower price target of $3.75 due to high risks, the company has a strong potential with its new RTD products and international growth. However, risks such as balance sheet/liquidity, competition, and changing consumer trends remain as potential roadblocks for the company's success in the health and wellness industry. Additionally, the company's high debt-to-cash ratio is concerning and could impact their financial stability.
This aggregate rating is based on analysts' research of Synergy CHC Corp and is not a guaranteed prediction by Public.com or investment advice.
SNYR Analyst Forecast & Price Prediction
Start investing in SNYR
Order type
Buy in
Order amount
Est. shares
0 shares